Heart failure and Diabetes mellitus are chronic complex medical conditions that are closely related and commonly coexist.Treatment options have varied over the years, but newer treatment modalities have developed which have improved prognosis and longevity of patients with these conditions. Unfortunately, despite these advances, the evidence base remains insufficient, and larger randomised control trials need to be conducted. Here we discuss the available evidence and treatment and management of these inter-related conditions.
Thomas Thom ; Nancy Haase; Wayne Rosamond et al. (2006) Heart Disease and Stroke Statistics - 2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Circulation113: e85-151.
2.
Nichols, GA, Gullion, CM, Koro, CE, Ephross, SA, Brown, JB (2004) The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care27: 1879-84.
3.
Mehta, RH, Ruane, TJ, McCargar, PA, Eagle, KA, Stalhandske, EJ (2000) The treatment of elderly diabetic patients with acute myocardial infarction: Insight from Michigan's Cooperative Cardiovascular Project. Arch Intern Med160: 1301-6.
4.
Gottdiener JS , Tracy RP, Arnold AM et al. (2000) Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol35: B1628-37.
Kannel, WB, McGee, DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA241: 2035-8.
7.
Nichols, GA, Hillier, TA, Erbey, JR, Brown, JB (2001) Congestive heart failure in type 2 diabetes: Prevalence, incidence, and risk factors. Diabetes Care24: 1614-9.
8.
Aronow, WS, Ahn, C. (1999) Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest115: 867-8.
9.
Davis, BR, Piller, LB, Cutler, JA et al. (2006) Role of diuretics in the prevention of heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation113: 2201-10.
10.
Stratton, IM , Adler, AI, Neil, AW et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ321: 405-12.
11.
Emmanuelle Vermes ; Anique Ducharme; Martial G. Bourassa; Myriam Lessard; Michel White; Jean-Claude Tardif et al. ( 2003) Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation107: 1291-6.
12.
King, H., Aubert, RE, Herman, WH (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care21: 1414-31.
13.
Cohn JN, Johnson G., Ziesche S. et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med325: 303-10.
14.
Das, SR et al. (2004) Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: A retrospective analysis from the Studies Of Left Ventricular Dysfunction (SOLVD) prevention trial . Am Heart J148: 883-8.
15.
Solang, L., Malmberg, K., Ryden, L. (1999) Diabetes mellitus and congestive heart failure . Eur Heart J20: 789-95.
16.
Alain G Bertoni; W. Gregory Hundley; Mark W Massing; Denise E Bonds; Gregory L Burke; David C Goff, Jr. ( 2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care27: 699-703.
17.
Ho, KK, Anderson, KM, Kannel, WB, Grossman, W., Levy, D. (1993) Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation88: 107-15.
18.
Vaur, L., Gueret, P., Lievre, M., Chabaud, S., Passa, P. (2003) Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the DIA-BHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care26: 855-60.
19.
Diabetes Prevention Program Research Group. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med346: 393-403.
20.
Sharon Ann Hunt; William T. Abraham; Marshall H. Chin et al. ( 2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation112: e154-e235.
21.
Flather MD, Yusuf S., Køber L. et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet355: 1575-81.
22.
Paul G.Shekelle, MichaelW. Rich, Sally C. Morton et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol41: 1529-1538.
23.
Masoudi FA, Rathore SS, Wang Y. et al. (2004) National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation110: 724-731.
24.
Large study group. (1987 ) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med316, 1429-1435.
25.
Pfeffer MA, Braunwald E., Moyé LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction . Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med327: 669-677.
26.
Pouleur, H. ; Rousseau, MF; van Eyll C.; Melin J.; Youngblood M.; Yusuf S. (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med325: 293-302.
27.
Kober L., Torp-Pedersen C., Carlsen JE et al. (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med333: 1670-6.
28.
Fan Fan Hou , Xun Zhang, Guo Hua Zhang et al. (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency . N Engl J Med354: 131-0.
29.
Wlodarczyk, JH, Keogh, A., Smith , K., McCosker, C. (2003) CHART: Congestive cardiac failure in hospitals, an Australian review of treatment . Heart Lung Circ12: 94-102.
30.
Packer M., Coats AJ, Fowler MB et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med344: 1651-8.
31.
Packer M., Bristow MR, Cohn JN et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med334: 1349-55.
32.
Erdmann, E. , Lechat, P., Verkenne , P., Wiemann, H. (2001) Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail3: 469-79.
33.
Cohn, JN, Tognoni, G. (2001) The Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med345: 1667-75.
34.
Young JB, Dunlap ME, Pfeffer MA et al. (2004) Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: Results of the CHARM low-left ventricular ejection fraction trials. Circulation110: 2618-26.
35.
Carr AA, Kowey PR, Devereux Rb B.D.B.I.H.L.L.L.P.S.S.Z.Z.E.J.S.S. (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol96: 1530-1536.
36.
Pitt B., Remme W., Zannad F. et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction . N Engl J Med348: 1309-21.
37.
Helderman JH , Elahi D., Andersen DK et al. (1983) Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium . Diabetes32: 106-11.
38.
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group (2003 ) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care26: 3264-72.
39.
Cubbon RM, Gale CP, Rajwani A. et al. (2008) Aspirin and mortality in patients with diabetes sustaining acute coronary ayndrome. Diabetes Care31: 363-5.
40.
S. Fateh-Moghadam, U., Plöckinger, N., Cabeza S.P.U.C.N.H. R.T.E.G.M.D.R.B.W.(2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol42: 99-103.
41.
Ajjan, R., Grant, PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis186: 240-59.
42.
Laurent Macchi ; Luc Christiaens; Severine Brabant et al. ( 2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res107: 45-9.
43.
Francesco Cipollone; Giovanni Ciabattoni; Paola Patrignani et al. (2000 ) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation102: 1007-13.
44.
Dunn, EJ, Ariëns, RAS, Grant, PJ (2005) The influence of type 2 diabetes on fibrin structure and function. Diabetologia48: 1198-206.
45.
Barry M., Massie MD, Joseph F., Collins ScD*, Susan E., Ammon et al. (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial. Circulation119: 1616-24.
46.
John GF Cleland; Melanie J. Calvert; Yves Verboven; Nick Freemantle (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med352: 1539-49.
47.
Bristow MR, Saxon LA, Boehmer J. et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med350: 2140-50.
48.
WT Abraham , WG Fisher, AL Smith et al. (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med346: 1845-53.
49.
Hoppe, UC, Freemantle, N., Cleland, JGF, Marijianowski, M., Erdmann, E. (2007) Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care30: 722-4.
50.
Large study group. (2000 ) Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol35: 1122-1129.
51.
Mark J Russo; Jonathan M Chen; Kimberly N, Hong et al. (2006) Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: An analysis of the United Network of Organ Sharing Database . Circulation114: 2280-7.
52.
Turner RC, Holman RR, Matthews DR (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet352: 837-53.
53.
Misbin, RI (2004) The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care27: 1791-3.
54.
Frederick A. Masoudi; Silvio E. Inzucchi; Yongfei Wang; Edward P. Havranek; JoAnne M. Foody; Harlan M. Krumholz et al. ( 2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation111: 583-90.
55.
Eurich, DT, Majumdar, SR, McAlister, FA, Tsuyuki, RT, Johnson, JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care28: 2345-51.
56.
Inzucchi, SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA287: 360-72.
57.
Guan Y.; Hao C.; Cha DR et al. (2005) Thiazolidinediones expand body fluid volume through PPAR[gamma] stimulation of ENaC-mediated renal salt absorption. Nat Med11: 861-6.
58.
Singh, S., Loke, YK, Furberg, CD (2007) Thiazolidinediones and heart failure: A teleo-analysis . Diabetes Care August 2007 vol. 30 no. 82148-2153.
59.
Richard W. Nesto; David Bell; Robert O. Bonow et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association . Circulation108: 2941-8.
60.
Smooke, S., Horwich, TB, Fonarow, GC (2005) Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J149:168-74.
